Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Research Helps Explain Idiosyncrasies of COVID-19

Jason Liebowitz, MD, FACR  |  November 23, 2021

He also stated that we do not yet have the longitudinal data to see what happens to these autoantibodies in patients over time. It remains to be seen if the formation of new-onset IgG autoantibodies in moderate to severe COVID-19 has implications for future development of immunodeficiency phenotypes or autoimmune disease in these patients.

Dr. Webb

MIS-C

The next talk was given by Kate Webb, MD, PhD, pediatric immunology clinician scientist at the University of Cape Town, South Africa, on the topic of SARS-CoV-2 antibody phenotype and immune gene expression in MIS-C. Dr. Webb explained that, to date, it has been unclear why some children with SARS-CoV-2 infection develop MIS-C while others do not. The aims of the study conducted by Dr. Webb and colleagues were to compare a cohort of children with evidence of exposure to SARS-CoV-2 and see which patients develop MIS-C, to look for differences in SARS-CoV-2 antibodies and to evaluate differences in immune gene expression among these patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers enrolled 33 children with MIS-C (mean age 6.9 years) and compared these individuals to 97 healthy children (30% of whom had been exposed to SARS-CoV-2 and 60% who were unexposed). From studying these children, Dr. Webb and her colleagues noted that SARS-CoV-2 antibody titers were no different in MIS-C compared to healthy exposed children and that spike antibody (IgG) titer does not change over time in patients with MIS-C. Dr. Webb and her colleagues also found that patients with MIS-C showed a distinct expression of immune genes as compared to healthy children, with a dynamic return of gene expression to normal when followed over time.

Dr. Vargas

TNFi or Rituximab Treatments

In the penultimate talk, Luisa M. Rojas Vargas, MD, Rheumatology Service of Hospital La Mancha Centro, Alcazar de San Juan, Spain, discussed a study assessing whether tumor necrosis factor inhibition (TNFi) or rituximab is related to a different course and severity of SARS-CoV-2 infection in patients with rheumatic diseases as compared to patients receiving other biologic therapies.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In this observational, retrospective, multicenter study, Dr. Vargas and colleagues enrolled 372 patients with rheumatic diseases who had received TNFi or rituximab from at least three months prior to the beginning of the COVID-19 pandemic until March 2021. Of these patients, 18% had confirmed SARS-CoV-2 infection, with 40% of these patients having a history of spondyloarthritis, 32% with rheumatoid arthritis and 12% with psoriatic arthritis.

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2021COVID-19interferonMultisystem Inflammatory Syndrome in Children (MIS-C)

Related Articles
    Bernard Chantal / shutterstock.com

    Diagnostic Challenges of MIS-C

    May 12, 2022

    During the peak of the coronavirus pandemic in Washington, D.C., we were asked to evaluate a 14-year-old boy admitted to the pediatric hospitalist service. He had been healthy until two weeks before, when he noted a sore throat, and soon after he developed fevers and rashes without congestion, shortness of breath, conjunctivitis or swollen lymph…

    The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era

    November 23, 2021

    New concepts in autoimmunity & immunology are being discovered daily in research being conducted to understand the SARS-CoV-2 virus and its implications for rheumatology & all fields of medicine. Here are some insights shared by experts during day 1 of the Basic and Clinical Research Conference.

    MIA Studio / shutterstock.com

    ACR Releases COVID-19 & MIS-C Clinical Guidance for Kids with Rheumatic Disease

    August 12, 2020

    The ACR has released clinical guidance documents for pediatric patients with rheumatic disease in the context of the COVID-19 pandemic, including one for multi-system inflammatory syndrome in children (MIS-C). Jay Mehta, MD, MS, an attending physician in the Division of Rheumatology and director of the Pediatric Rheumatology Fellowship at the Children’s Hospital of Philadelphia (CHOP),…

    ACR Convergence 2020: COVID-19 Hyper-Inflammation in Kids

    November 9, 2020

    ACR CONVERGENCE 2020—Among the many ways in which the COVID-19 pandemic has changed the face of modern medicine is the emergence of multisystem inflammatory syndrome in children (MIS-C), a rare but serious condition that shares many features of Kawasaki disease (KD). With this topic in mind, leading pediatric experts from around the world came together…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences